Page last updated: 2024-10-25

ciglitazone and Atherogenesis

ciglitazone has been researched along with Atherogenesis in 2 studies

ciglitazone: structure given in second source; PPAR agonist used for type II diabetes
ciglitazone : An aromatic ether that consists of 1,3-thiazolidine-2,4-dione with position 5 substituted by a 4-[(1-methylcyclohexyl)methoxy]benzyl group. A selective PPARgamma agonist.

Research

Studies (2)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's0 (0.00)29.6817
2010's2 (100.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Hofnagel, O1
Engel, T1
Severs, NJ1
Robenek, H1
Buers, I1
Liu, H1
Wang, S1
Sun, A1
Huang, D1
Wang, W1
Zhang, C1
Shi, D1
Chen, K1
Zou, Y1
Ge, J1

Other Studies

2 other studies available for ciglitazone and Atherogenesis

ArticleYear
SR-PSOX at sites predisposed to atherosclerotic lesion formation mediates monocyte-endothelial cell adhesion.
    Atherosclerosis, 2011, Volume: 217, Issue:2

    Topics: Animals; Anti-Inflammatory Agents; Atherosclerosis; Cell Adhesion; Cells, Cultured; Chemokine CXCL16

2011
Danhong inhibits oxidized low-density lipoprotein-induced immune maturation of dentritic cells via a peroxisome proliferator activated receptor γ-mediated pathway.
    Journal of pharmacological sciences, 2012, Volume: 119, Issue:1

    Topics: Atherosclerosis; Cytokines; Dendritic Cells; Drugs, Chinese Herbal; Endocytosis; Humans; Lipoprotein

2012